Showing 6901-6910 of 7640 results for "".
- New from Suneva: Regenica® Rejuvenating Dual Serumhttps://practicaldermatology.com/news/new-from-suneva-regenica-rejuvenating-dual-serum/2458620/Suneva Medical, Inc., is rolling out Regenica® Rejuvenating Dual Serum, the newest addition to the Regenica® skin care line. The dual chamber serum is created via growth factor
- Topical RHA Technology Boosts Skin Rehydration, Rejuvenationhttps://practicaldermatology.com/news/topical-rha-technology-boosts-skin-rehydration-and-rejuvenation/2458621/Crosslinked resilient Hyaluronic Acid (RHA™) bests non-crosslinked (linear) low and high molecular weight hyaluronic acid at increasing water content of the skin, maintaining skin integrity and improving skin barrier function, new research suggests. The findings appear in the
- Next Stop FDA Approval? Dupilumab Improves Symptoms in Moderate-to-Severe ADhttps://practicaldermatology.com/news/next-stop-fda-approval-dupilumab-improves-symptoms-in-moderate-to-severe-ad/2458625/Dupilumab helps improve the signs and symptoms of moderate-to-severe atopic dermatitis (AD) in adults, according to two late stage clinical trials. The U.S. Food and Drug Administration (FDA) granted dupilumab Breakthrough Therapy designation in AD in November 2014. U.S. regulatory
- Rosacea Awareness Month Highlights Potential Increased Health Riskshttps://practicaldermatology.com/news/rosacea-awareness-month-highlights-potential-increased-health-risks/2458624/New studies are now revealing potential associations between rosacea and increased risks of cardiovascular disease, gastrointestinal disease, certain types of cancer and many other systemic illnesses. The National Rosacea Society (NRS) has designated April as Rosacea Awareness Month to alert the
- Tissue Regeneration Leader Takes Home 2016 Furumoto Award at ASLMS 2016https://practicaldermatology.com/news/tissue-regeneration-leader-takes-home-2016-furumoto-award-at-aslms-2016/2458627/Praveen Arany, DDS, PhD will receive the 2016 ASLMS Dr. Horace Furumoto Innovations Young Investigator Award during the Plenary Session at ASLMS 2016, the Annual Conference of the American Society for Laser Medicine & Surgery, Inc. (ASLMS).
- North America's Scar Treatment Poised for Growth Spurt by 2022https://practicaldermatology.com/news/north-america-scar-treatment-market-set-to-grow-by-2022/2458629/Scar treatment will be a hot growth area in coming years, according to a new report by Persistence Market Research. The report cites a rising incidence of burn and trauma cases and an increasing preval
- Vitals Report: National Average Wait Time Down Nearly 10% since 2009https://practicaldermatology.com/news/vitals-report-national-average-wait-time-down-nearly-10-since-2009/2458630/When it comes to waiting for a doctor’s appointment, most patients are waiting 19 minutes, 19 seconds, according to Vitals 7th annual wait time report This is down nearly 10 percent from the average 21 minutes and 18 seconds patients once sp
- Let the Sun Shine In? Research Reveals Why Sunbathers May Live Longer than Sun Avoidershttps://practicaldermatology.com/news/let-the-sun-shine-in-research-reveals-why-sunbathers-may-live-longer-than-sun-avoiders/2458634/Sunbathers tend to live longer than their shade-seeking counterparts despite their increased risk for skin cancer, but why? New research suggests that a decrease in heart disease and noncancer/non-heart disease deaths may explain the paradox.
- FDA Greenlights Taltz for Psoriasishttps://practicaldermatology.com/news/fda-greenlights-taltz-for-psoriasis/2458635/The U.S. Food and Drug Administration approved the IL-17A blocker Taltz (ixekizumab) for adults with moderate-to-severe plaque psoriasis. Taltz is marketed by Indianapolis, Indiana-based Eli Lilly and Company. Given via
- FDA Proposes Ban on Most Powdered Medical Gloveshttps://practicaldermatology.com/news/fda-proposes-ban-on-most-powdered-medical-gloves/2458639/The FDA has proposed a ban on most powdered gloves in the United States. While use of these gloves is decreasing, they pose an unreasonable and substantial risk of illness or injury to health care providers, patients and other individuals who are exposed to them, which cannot be corrected t